David Amsellem

Stock Analyst at Piper Sandler

(4.01)
# 666
Out of 4,497 analysts
94
Total ratings
50%
Success rate
11.2%
Average return

25 Stocks

Pacira BioSciences
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $19.37
Upside: +116.83%
Corcept Therapeutics
Jul 1, 2024
Reiterates: Overweight
Price Target: $35
Current: $33.88
Upside: +3.31%
Amphastar Pharmaceuticals
Jun 27, 2024
Reiterates: Overweight
Price Target: $71
Current: $39.61
Upside: +79.25%
Teva Pharmaceutical
May 13, 2024
Reiterates: Overweight
Price Target: $19$20
Current: $16.81
Upside: +18.98%
Xeris Biopharma Holdings
May 10, 2024
Reiterates: Overweight
Price Target: $4$3
Current: $2.37
Upside: +26.85%
Revance Therapeutics
May 10, 2024
Reiterates: Overweight
Price Target: $20$11
Current: $3.64
Upside: +202.61%
Collegium Pharmaceutical
May 10, 2024
Downgrades: Neutral
Price Target: $39
Current: $32.36
Upside: +20.52%
Organon & Co.
Apr 29, 2024
Maintains: Overweight
Price Target: $22$24
Current: $20.98
Upside: +14.39%
Aquestive Therapeutics
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.20
Upside: +212.50%
Alkermes
Apr 1, 2024
Reiterates: Overweight
Price Target: $39
Current: $24.83
Upside: +57.07%
Viatris
Mar 28, 2024
Reiterates: Neutral
Price Target: $11$13
Current: $11.84
Upside: +9.80%
Amneal Pharmaceuticals
Mar 21, 2024
Maintains: Overweight
Price Target: $6$8
Current: $7.24
Upside: +10.50%
Jazz Pharmaceuticals
Mar 20, 2024
Reiterates: Overweight
Price Target: $171$188
Current: $109.01
Upside: +72.46%
Avadel Pharmaceuticals
Mar 5, 2024
Maintains: Overweight
Price Target: $18$23
Current: $16.20
Upside: +41.98%
Supernus Pharmaceuticals
Feb 28, 2024
Maintains: Overweight
Price Target: $45$41
Current: $30.25
Upside: +35.54%
Ironwood Pharmaceuticals
Feb 16, 2024
Maintains: Overweight
Price Target: $20$21
Current: $6.72
Upside: +212.50%
Axsome Therapeutics
Jan 16, 2024
Maintains: Overweight
Price Target: $90$113
Current: $84.85
Upside: +33.18%
Cerevel Therapeutics Holdings
Dec 7, 2023
Downgrades: Neutral
Price Target: $33$45
Current: $42.90
Upside: +4.90%
Cara Therapeutics
Nov 14, 2023
Downgrades: Neutral
Price Target: $12$1
Current: $0.34
Upside: +190.28%
Neurocrine Biosciences
Nov 1, 2023
Maintains: Neutral
Price Target: $95$100
Current: $145.69
Upside: -31.36%
Harmony Biosciences Holdings
Oct 16, 2023
Maintains: Overweight
Price Target: $72$42
Current: $32.04
Upside: +31.09%
OptiNose
Aug 11, 2023
Maintains: Overweight
Price Target: $4$3
Current: $1.06
Upside: +183.02%
Eagle Pharmaceuticals
Aug 9, 2023
Downgrades: Underweight
Price Target: $26$17
Current: $5.87
Upside: +189.61%
Bausch Health Companies
Sep 9, 2022
Maintains: Neutral
Price Target: $7$6
Current: $7.60
Upside: -21.05%
Evofem Biosciences
May 25, 2022
Maintains: Overweight
Price Target: $3,750$250
Current: $0.01
Upside: +2,380,852.38%